Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing life-changing medicines for patients battling challenging diseases. Their lead therapeutic asset, Trappsol® Cyclo™, is a proprietary formulation of hydroxypropyl beta cyclodextrin, which has demonstrated encouraging results in managing cholesterol transport. This technology is being explored as a potential treatment for Niemann-Pick Disease Type C1 (NPC), a rare, fatal genetic disorder, and Alzheimer's disease, an irreversible, progressive neurological disorder.

Cyclo Therapeutics is committed to collaborating with patients, families, and advocacy organizations. They are actively engaged in clinical trials for both NPC and Alzheimer's disease and believe in the importance of transparency and communication. The company's dedication to scientific innovation, coupled with their strong focus on patient support, positions them as a leader in the development of novel therapies for these challenging diseases.

Cyclo Therapeutics is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with challenging diseases. Their focus is on the development of a cyclodextrin-based product for the potential treatment of Niemann-Pick Disease Type C, a rare and fatal genetic disease, and for Alzheimer’s Disease.

Cyclo Therapeutics promotes a collaborative and patient-centric culture. Their commitment to patients is evident in their efforts to engage with the patient community, share progress, and incorporate their feedback into their decision-making. They emphasize transparency, open communication, and collaboration with advocacy organizations. This focus on collaboration, both internally and externally, suggests a culture that values diverse perspectives and a shared commitment to improving the lives of those affected by the diseases they are working to treat.

Cyclo Therapeutics is committed to fostering a diverse, equitable, and inclusive environment. The company publicly discloses its Board Diversity Matrix, showcasing efforts towards gender and ethnic representation. While specific DEI initiatives are not explicitly stated, their commitment to collaborating with advocacy organizations and patient communities suggests a broader focus on inclusivity and representation within their work.